Abstract
Postmastectomy irradiation has been analyzed in several randomized trials, usually without the presence of systemic therapy. Overview analysis of these studies has shown that, although postmastectomy irradiation generally reduces the locoregional recurrence rate by a factor of 3, this is not transferred into a general long-term survival benefit. Recently, a clinically relevant survival gain from adjuvant radiotherapy has been shown in high-risk premenopausal patients also treated with adjuvant chemotherapy. There are now 11 published trials, including more than 6000 patients, in which the effect of postmastectomy radiotherapy has been evaluated in the presence of adjuvant systemic therapy. This article reviews the available data from these trials, as well as problems in their design, sample size, inclusion criteria, quality, and extent of treatments, and length of follow-up time.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
